Abstract
Objective: To investigate the effect of Mongolia Astragalus that is one of Chinese herbal medicine originating in Longxi of Gansu Province on cardiac and nephritic function in patients of essential hypertension (EH) with metabolic syndrome (MetS). Design and method: This study was designed as a prospective, open label, parallel randomized controlled trial. Two hundred and twenty-six EH patients with MetS over the age of 18 years were selected. Patients were randomly assigned to control group (adopted conventional medical treatment), Astragalus group 1 (added Astragalus capsules10 g/d) and Astragalus group 2 (added Astragalus capsules 5 g/d). Some indicators of the cardiac anatomy structures, the cardiac systolic function and diastolic function were measured by M-mode echocardiography, two-dimensional echocardiography, doppler echocardiographic determination and tissue Doppler imaging. The level of urinary microalbuminuria (MAU) was evaluated by radioimmunoassay. In addition, the estimated glomerular filtration rate (eGFR) was calculated by Modification of Diet in Renal Disease formulas. The changes of related indicators for cardiac and nephritic function were compared between pre-treatment and post-treatments after 12 months follow-up. Research programs was registered with the Chinese Clinical Trial Register Website and approved by The Ethics Committee of Lanzhou University Second Hospital. Each patient signed an informed consent. Results: The all metabolic related indicators did not differ in three groups (P > 0.05). The cardiac anatomy structure and the indicators of cardiac systolic function have no significant difference in these three groups (P > 0.05). The ratio of early diastolic peak flow velocity and early diastolic mitral annular velocity ratio (E / E ’) was reduced in Astragalus group1 than those of in Astragalus group 2 (P < 0.05). And it in both Astragalus group1 and Astragalus group2 were all superior to that in conventional treatment group (P < 0.05). Astragalus had a significant effect on MAU reduction (P = 0.044), and this effect was dosage related of astragalus (P = 0.036). Conclusions: Comparing with only conventional treatment, Astragalus combined with conventional treatment could improve the left ventricular diastolic function and reduce the MAU at certain extent in EH patients with MetS. These effects were more superior within high-dose of Astragalus than those of low-dose Astragalus in some aspects.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
